Fulcrum Therapeutics (NASDAQ:FULC) Cut to Underweight at JPMorgan Chase & Co.

Fulcrum Therapeutics (NASDAQ:FULC) was downgraded by stock analysts at JPMorgan Chase & Co. from an “overweight” rating to an “underweight” rating in a report issued on Wednesday.

A number of other research firms also recently weighed in on FULC. Piper Sandler downgraded shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Tuesday, April 21st. HC Wainwright downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price target for the company. in a research note on Tuesday. Citigroup downgraded shares of Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a research note on Tuesday. Finally, Wall Street Zen raised shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 2nd. One analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average price target of $8.20.

Fulcrum Therapeutics Trading Down 51.1%

Shares of NASDAQ FULC opened at $3.14 on Wednesday. Fulcrum Therapeutics has a 1-year low of $2.83 and a 1-year high of $15.74. The company has a market cap of $209.22 million, a PE ratio of -2.73 and a beta of 2.93. The company has a 50-day moving average of $7.23 and a two-hundred day moving average of $9.22.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings results on Monday, April 27th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. As a group, equities research analysts forecast that Fulcrum Therapeutics will post -1.16 earnings per share for the current year.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several large investors have recently bought and sold shares of FULC. Cubist Systematic Strategies LLC bought a new stake in Fulcrum Therapeutics in the first quarter valued at approximately $164,000. Jane Street Group LLC increased its stake in Fulcrum Therapeutics by 62.1% in the first quarter. Jane Street Group LLC now owns 117,816 shares of the company’s stock valued at $339,000 after purchasing an additional 45,157 shares in the last quarter. Creative Planning bought a new stake in Fulcrum Therapeutics in the second quarter valued at approximately $117,000. Legal & General Group Plc increased its stake in Fulcrum Therapeutics by 230.2% in the second quarter. Legal & General Group Plc now owns 17,461 shares of the company’s stock valued at $120,000 after purchasing an additional 12,173 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in Fulcrum Therapeutics by 7.0% in the second quarter. American Century Companies Inc. now owns 132,349 shares of the company’s stock valued at $911,000 after purchasing an additional 8,638 shares in the last quarter. Institutional investors own 89.83% of the company’s stock.

Key Fulcrum Therapeutics News

Here are the key news stories impacting Fulcrum Therapeutics this week:

• Negative Sentiment: Fulcrum halted its pociredir program after FDA feedback raised serious safety concerns, wiping out its lead clinical asset and prompting a strategic review that could include a sale or merger. Reuters: Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
• Negative Sentiment: Multiple law firms launched investigations into whether Fulcrum and its executives violated securities laws after the stock’s steep drop, adding legal overhang and investor uncertainty. PR Newswire: Fulcrum Therapeutics, Inc. Investigation Initiated
• Negative Sentiment: Several analysts cut ratings, including downgrades from Cantor Fitzgerald, Leerink Partners, Stifel, and HC Wainwright, reflecting a sharply less optimistic outlook after the program termination. Tickerreport.com: Fulcrum Therapeutics was downgraded by Cantor Fitzgerald

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small?molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.